- Home
- HNVR vs CRBP Comparison
HNVR vs CRBP Comparison
Compare HNVR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HNVR | CRBP |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 170.3M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | HNVR | CRBP |
|---|---|---|
| Price | $24.07 | $8.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $24.75 | ★ $50.29 |
| AVG Volume (30 Days) | 14.5K | ★ 192.9K |
| Earning Date | 01-27-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $68,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.56 | $220.00 |
| P/E Ratio | $15.47 | ★ N/A |
| Revenue Growth | ★ 10.44 | N/A |
| 52 Week Low | $17.47 | $4.64 |
| 52 Week High | $27.00 | $20.56 |
Technical Indicators
Market Signals| Indicator | HNVR | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 46.46 |
| Support Level | $21.51 | $7.72 |
| Resistance Level | $24.33 | $8.66 |
| Average True Range (ATR) | 0.66 | 0.44 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 53.90 | 88.35 |
Price Performance
Historical ComparisonAbout HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.